Head-to-head · Cost-Efficiency Index
NextMeds vs He & She MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NextMeds
Shoppers who will call out and verify the exact price at checkout, given the site shows several different promo numbers at once.
Visit NextMedsHe & She MD
Shoppers comparing injectable semaglutide specifically, where the advertised $199 genuinely is the standing price — not oral semaglutide or tirzepatide, which roll higher after 6 months.
Visit He & She MDThe verdict
NextMeds takes it, leading the Cost-Efficiency Index 74 to 71. NextMeds is a compounded-GLP-1 telehealth platform naming a real clinical group (Lion MD, led by two NPI-verifiable physicians) and six named compounding pharmacies — unusually transparent on that front. He & She MD still earns a C — Shoppers comparing injectable semaglutide specifically, where the advertised $199 genuinely is the standing price — not oral semaglutide or tirzepatide, which roll higher after 6 months.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NextMeds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NextMeds | He & She MD |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 71/100 |
| Semaglutide / mo | $79/mo (starting dose, promotional rate, compounded) | $199/mo (month to month, compounded; every lower rate is a prepaid term) |
| Tirzepatide / mo | $129/mo (starting dose, promotional rate, compounded) | $299/mo (month to month, compounded; every lower rate is a prepaid term) |
| Semaglutide / yr (modeled) | $948 | $2,388 |
| Tirzepatide / yr (modeled) | $1,548 | $2,388 |
| Coverage | All 50 states | All states except Louisiana (GLP-1) |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #61 | #65 |
NextMeds
74/100Where the value is
- Names a real, NPI-verifiable clinical group (Lion MD: Dr. Ana Lisa Carr, Dr. Kelly Tenbrink) rather than an anonymous provider network
- Names six real compounding pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills) instead of one generic claim
- Claims and states 'We service all 50 states'
The tradeoffs
- The live site shows at least three different headline promo prices ($69/$79/$89 for semaglutide) concurrently or near-concurrently, with no clear single 'current' number — a real transparency problem
- Aggressive countdown-timer urgency tactics ('Price increases in...', 'OFFER ENDS AUGUST 10TH AT MIDNIGHT!') are used to pressure signup
He & She MD
71/100Where the value is
- Compounded semaglutide and tirzepatide (injectable or oral), with brand-name access to Ozempic, Wegovy, and Zepbound also offered
- Named pharmacy (F&F Pharmacies Inc DBA Jungle Jim's Pharmacy, Fairfield OH) and named CMO (Dr. Ozita Cooper, MD)
- Free expedited shipping and unlimited board-certified clinician access
The tradeoffs
- Its own FAQ says the pharmacy it names holds a license in 44 US states, none in California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia or Delaware, and “cannot dispense sterile compounds” — while the same FAQ says GLP-1s ship everywhere except Louisiana. Injectable GLP-1s are sterile compounds, and the site never says which of its two pharmacies covers the gap
- The uniform '$199 to start' banner across all three tracks obscures that only injectable semaglutide holds at $199 ongoing — oral semaglutide rolls to $239/mo and injectable tirzepatide rolls to $289/mo after the first 6-month cycle
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.